A Nabiximols Spinal-Cord-Injury Trial Found Similar Pain Changes With Spray and Placebo
A trial of THC:CBD spray for spinal-cord-injury neuropathic pain reported nearly identical average pain changes with active treatment and placebo. Improvement from baseline alone did not demonstrate an added spray benefit.
The comparison concerned a defined pain population
The review summarizes a randomized study registered as NCT01606202. Its evidence table lists 116 randomized participants and 106 completers over three weeks. Patients had intractable neuropathic pain associated with spinal cord injury. The intervention was nabiximols, a standardized THC:CBD oromucosal spray, rather than isolated CBD or smoked marijuana.
Both groups changed by a similar amount
Mean pain-score reductions were 0.74 points with the spray and 0.69 with placebo on the 0–10 numerical rating scale. The reported p-value was 0.71. Those results did not demonstrate a statistically significant treatment difference under the trial conditions. Quoting the active group’s reduction without the placebo reduction would give an incomplete account of efficacy.
A null result also has boundaries
The finding does not establish exact equivalence or rule out every possible benefit in every patient. The trial duration, selected population and uncertainty around the effect constrain that inference. It also should not be replaced by positive findings from another neuropathic-pain diagnosis simply because both conditions involve nerve pain. Conversely, this study cannot invalidate every later trial using a different formulation or schedule. For interpretation, keep the injury type, preparation, comparator and short observation period attached to the result. The review supplies a condition-specific negative comparison, rather than proof that all cannabinoid analgesia succeeds or fails as a single category.
Related analysis: the broader findings and limitations of this research.
Research cited
The study observations discussed here are reported in the supplied review: Überall (2020). A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. Journal of Pain Research.
